Abstract
Sulfamerazine (monomethylsulfadiazine) was synthesized by Roblin and his co-workers 1 and has been used by several investigators in the treatment of a variety of clinical infections. 2 Since its therapeutic activity is apparently comparable to that of sulfadiazine, sulfathiazole and sulfapyridine, it is important to determine whether it possesses any advantage over those drugs with regard to toxic reactions. Evidence is conclusive 3 that sulfadiazine is less toxic than sulfathiazole and sulfapyridine, and for this reason it is recommended more frequently for systemic use than any other sulfonamide at the present time. In order to evaluate the toxicity of the more recently introduced sulfamerazine, we have at this time reviewed the records on all the patients observed by us to whom sulfamerazine 4 or sulfadiazine 4 was administered. These patients were in the wards of the Gallinger Municipal Hospital 5 or in the private practice of one of us. Altogether
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
